Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: is oral renin inhibition the solution?

Bibliography

• GARG R, YUSEF S, FOR THE COLLABORATIVE GROUP ON ACE INHIBITOR TRIALS: Overview of randomised trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J. Am. Med. Assoc. (1995) 273:1450-1456.
   Google Scholar
• LEE AFC, MACFADYEN RJ, STRUTHERS AD: Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur. J. Heart Fail. (1999) 1:401-406.
   Google Scholar
• SWEDBERG K, ENEROTH P, KJEKSHUS J, WILHELMSEN L FOR THE CONSENSUS TRIAL STUDY GROUP: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation (1990) 82:1730-1736.
   PubMed Web of Science ®Google Scholar
• CANDY GP, SKUDICKY D, MUELLER UK et al.: Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1999) 83:740-744.
   PubMedGoogle Scholar
• DELLGREN G, ERIKSSON MJ, BLANGE I et al.: Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis. Am. J. Cardiol. (1999) 84:909-913.
   PubMedGoogle Scholar
• ANDERSSON B, SYLVEN C: The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J. Am. Coll. Cardiol. (1996) 28:162-167.
   PubMed Web of Science ®Google Scholar
• VANCURA V, HUBACEK J, MALEK I et al.: Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy? Am. J. Cardiol. (1999) 83:461-462.
   PubMedGoogle Scholar
• DANSER AH, SCHALEKAMP MA, BAX WA et al.: Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation (1995) 92:1387-1388.
   PubMed Web of Science ®Google Scholar
• DAVIS GK, MILLNER RW, ROBERTS DH: Angiotensin converting enzyme (ACE) gene expression in the human left ventricle: effect of ACE gene insertion/deletion polymorphism and left ventricular function. Eur. J. Heart Fail. (2000) 2:253-256.
   Google Scholar
• MARIANTONIETTA CICOIRA M, LUISA ZANOLLA L, ANDREA ROSSI A et al.: Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) Inhibitor administration in chronic heart failure is associated with ACE DD genotype. J. Am. Coll. Cardiol. (2001) 37:1808-1812.
   PubMedGoogle Scholar
• WILSON TANG WH, VAGELOS RH, YEE YG, FOWLER MB: Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. Am. Heart J. (2004) 148:889-894.
   PubMedGoogle Scholar
• SO WY, MA RCW, OZAKI R et al.: Angiotensin-converting enzyme (ACE) inhibition in Type 2, diabetic patients – interaction with ACE insertion/deletion polymorphism. Kidney Int. (2006) 69:1438-1443.
   PubMedGoogle Scholar
• PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349:1893-1906.
   PubMed Web of Science ®Google Scholar
• MCMURRAY JJ, OSTERGREN J, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767-771.
   PubMed Web of Science ®Google Scholar
• AZIZI M, WEBB R, NUSSBERGER J, HOLLENBERG NK: Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens. (2006) 24:243-456.
   PubMed Web of Science ®Google Scholar
• NARUSE M, TANABE A, SATO A et al.: Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension (2002) 40:28-33.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348:1309-1321.
   PubMed Web of Science ®Google Scholar
• VAN DE WAL RM, PLOKKER HW, LOK DJ et al.: Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int. J. Cardiol. (2006) 106:367-372.
   PubMedGoogle Scholar
• URATA H, KINOSHITA A, MISONO KS, BUMPUS FM, HUSAIN A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. (1990) 265:22348-22357.
   PubMed Web of Science ®Google Scholar
• GEARY KM, HUNT MK, PEACH MJ, GOMEZ RA, CAREY RM: Effects of angiotensin converting enzyme inhibition, sodium depletion, calcium, isoproterenol, and angiotensin II on renin secretion by individual renocortical cells. Endocrinology (1992) 131:1588-1594.
   PubMedGoogle Scholar
• BENEDICT CR, FRANCIS GS, SHELTON B et al.: Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. Am. J. Cardiol. (1995) 75:1151-1157.
   PubMedGoogle Scholar
• HOLLENBERG NK: Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition. J. Am. Soc. Nephrol. (1999) 10(Suppl. 11):S239-S242.
   PubMedGoogle Scholar
• WILLIAMS GH: Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail. Rev. (2005) 10:7-13.
   Google Scholar
• KENNON B, INGRAM MC, FRIEL EC et al.: Aldosterone synthase gene variation and adrenocortical response to sodium status, angiotensin II and ACTH in normal male subjects. Clin. Endocrinol. (2004) 61:174-181.
   PubMedGoogle Scholar
• ROSSI GP: Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists? Curr. Hypertens. Rep. (2006) 8:262-268.
   Google Scholar
• NISHIKAWA T, SUEMATSU S, SAITO J et al.: Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J. Steroid Biochem. Mol. Biol. (2005) 96:309-316.
   PubMed Web of Science ®Google Scholar
• DZAU VJ: Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension (2001) 37:1047-1052.
   PubMed Web of Science ®Google Scholar
• MAIBAUM J, FELDMAN DL: Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin. Ther. Patents (2003) 13:589-603.
   Web of Science ®Google Scholar
• ZAMAN MA, OPARIL S, CALHOUN DA: Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov. (2002) 1:621-636.
   Google Scholar
• FISHER ND, HOLLENBERG NK: Is there a future for renin inhibitors? Expert Opin. Invest. Drugs (2001) 10:417-426.
   Google Scholar
• STANTON A: Potential of renin inhibition in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. (2003) 4:6-10.
   Google Scholar
• NUSSBERGER J, WUERZNER G, JENSEN C, BRUNNER HR: Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension (2002) 39:e1-e8.
   PubMed Web of Science ®Google Scholar
• BURTON J, CODY RJ, HERD JA, HABER E: Specific inhibition of renin by an angiotensinogen analog: studies in sodium depletion and renin-dependent hypertension. Proc. Natl. Acad. Sci. (1980) 77:5476-5479.
   Google Scholar
• ZUSMAN RM, BURTON J, CHRISTENSEN D, NUSSBERGER J, DODDS A, HABER E: Hemodynamic effects of a competitive renin inhibitory peptide in humans. Evidence for multiple mechanisms of action. Trans. Assoc. Am. Phys. (1983) 96:365-374.
   Google Scholar
• DZAU VJ, KOPELMAN RI, BARGER AC, NUSSBERGER J, HABER E: Comparison of renin-specific IgG and antibody fragment in studies of blood pressure regulation. Am. J. Physiol. (1984) 246:H404-H409
   PubMed Web of Science ®Google Scholar
• O’BRIEN E, BARTON J, NUSSBERGER J, MULCAHY D, JENSEN C, DICKER P, STANTON A: Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2006 Dec 11; [Epub ahead of print] Full ref available?
   Google Scholar
• AZIZI M, MENARD J, BISSERY A et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. (2004) 15:3126-3133.
   PubMed Web of Science ®Google Scholar
• STANTON A, JENSEN C, NUSSBERGER J, O’BRIEN E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 42:1137-1143.
   PubMed Web of Science ®Google Scholar
• POOL JL, SCHMIEDER RE, AZIZI M et al.: Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am. J. Hypertens. (2007) 20:11-20.
   PubMed Web of Science ®Google Scholar
• VILLAMIL A, CHRYSANT SG, CALHOUN D et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. (2007) 25:217-226.
   PubMed Web of Science ®Google Scholar
• VAIDYANATHAN S, JERMANY J, YEH C, BIZOT MN, CAMISASCA R: Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br. J. Clin. Pharmacol. (2006) 62:690-698.
   PubMed Web of Science ®Google Scholar
• DIETERLE W, CORYNEN S, VAIDYANATHAN S, MANN J: Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int. J. Clin. Pharmacol. Ther. (2005) 43:527-535.
   Web of Science ®Google Scholar
• DIETERLE W, CORYNEN S, MANN J: Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br. J. Clin. Pharmacol. (2004) 58:433-436.
   PubMed Web of Science ®Google Scholar
• ALLIKMETS K: Aliskiren. Curr. Opin. Investig. Drugs (2002) 3:1479-1482.
   Google Scholar
• STANTON A: Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am. J. Cardiovasc. Drugs (2003) 3:389-394.
   Google Scholar
• STRAUSS MH, HALL AS: Angiotensin receptor blockers may increase risk of myocardial infarction: unravelling the ARB-MI paradox. Circulation (2006) 114:838-854.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, LI Y, RICHART T: Oral renin inhibitors. Lancet (2006) 368:1449-1456.
   PubMed Web of Science ®Google Scholar